REFERENCES
  1. Lythgoe MP, Middleton P. Ongoing clinical trials for the management of the COVID-19 pandemic, trends in pharmacological sciences (2020).
  2. Liu C, Zhou Q, Li Y, et.al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci . 2020;6(3):315-331.
  3. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med . 2020;NEJMoa2001282.
  4. Chen ZW, Hu JJ, Zhang ZW, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial.medRxiv . 2020.
  5. Kalil AC. Treating COVID-19-Off-Label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA . 2020.
  6. Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med . 2017;377(1):62-70..
  7. Welliver R, Monto AS, Carewicz O, et.al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001;285(6):748-54.
  8. World Health Organization, & World Health Organization. (2020). Report of the who-china joint mission on coronavirus disease 2019 (covid-19). Available on-line: https://www. who. int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report. pdf.
  9. Mizumoto K, Kagaya K, Zarebski A, et.al. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020.Euro Surveill . 2020;25(10):2000180.
  10. Wang Y, Liu Y, Liu L, et.al. Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-Coronavirus-2 in Shenzhen. China. J Infect Dis . 2020.
  11. Wu Z and McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA . 2020.
  12. Onder G, Rezza G, Brusaferro S. Case-Fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA . 2020.
  13. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi . 2020;41(2):145-151.
  14. United Nations, Department of Economic and Social Affairs, Population Division (2019). World Population Prospects 2019: Volume I: Comprehensive Tables. Available on line:https://population.un.org/wpp/Publications/Files/WPP2019_Volume-I_Comprehensive-Tables.pdf.
  15. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:343-346.
  16. O’Dwyer DN, Dickson RP, Moore BB. The lung microbiome, lmmunity, and the pathogenesis of chronic lung disease. J Immunol . 2016;196(12):4839-47.
  17. Loverdos K, Bellos G, Kokolatou L, et.al. Lung microbiome in asthma: current perspectives. J Clin Med . 2019;8(11):1967.
  18. Coutard B, Valle C, de Lamballerie X, et.al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res . 2020;176:104742.
  19. Matsuyama S, Nao N, Shirato K, et.al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A . 2020;117(13):7001-7003.
  20. Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.Circulation . 2005;111(20):2605-10.
  21. Patel AB, Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: What Is the Evidence?JAMA . 2020.
  22. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–544.
  23. Chen L, Xiong J, Bao L, et.al. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398–400.
  24. van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016;374(1):33-42.
  25. Burnouf T, Radosevich M. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J.2003;9(4):309.
  26. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA. 2020;e204783.
  27. Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020;92(5):479–490.
  28. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 S0092-8674(20)30229-4.
  29. Wang K, Chen W, Zhou YS, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. bioRxiv . 2020.
  30. Ibrahim IM, Abdelmalek DH, Elshahat ME, et.al. COVID-19 spike-host cell receptor GRP78 binding site prediction. J Infect . 2020.
  31. Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun . 2020;11(1):1620.
  32. Wang PH, Cheng Y. Increasing host cellular receptor—angiotensin-converting enzyme 2 (ACE2) expression by coronavirus may facilitate 2019-nCoV infection. bioRxiv . 2020.
  33. Simmons G, Bertram S, Glowacka I, et al. Different host cell proteases activate the SARS-coronavirus spike-protein for cell–cell and virus–cell fusion. Virology . 2011; 413:265-74.
  34. Devaux CA, Rolain JM, Colson P, et.al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;105938.
  35. Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet . 2020;395(10223): e30-e31.
  36. Wang ML, Cao RY, Zhang LK, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res . 2020;30(3):269-271.
  37. Sheahan TP, Sims AC, Graham RL, et.al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.Sci Transl Med . 2017;9(396):eaal3653.
  38. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis . 2020.
  39. Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola virus disease terapeutics. N Engl J Med . 2019;381(24):2293-2303.
  40. de Wit E, Feldmann F, Cronin J, et.al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A . 2020;117(12):6771-6776.
  41. Adelusi SA, Salako LA. Kinetics of the distribution and elimination of chloroquine in the rat. Gen Pharmacol . 1982;13:433-437.
  42. McChesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med . 1983;75(1A):11-8.
  43. Jin Y, Yang H, Ji W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses . 2020;12(4).
  44. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature . 2020.
  45. McLean HQ, Belongia EA, Kieke BA, et al. Impact of late oseltamivir treatment on influenza symptoms in the outpatient setting: results of a randomized trial. Open Forum Infect Dis . 2015;2(3):ofv100.
  46. Gao JJ, Tian ZX, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends . 2020;14(1):72-73.
  47. Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi . 2020;12;43(3):185-188.
  48. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial. Int J Antimicrob Agents . 2020.
  49. Chen J, Liu DP, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19).Journal of ZheJiang University . 2020.
  50. Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect D . 2020.
  51. Bi QF, Wu YS, Mei SJ , et al. Epidemiology and transmission of COVID-19 in Shenzhen China: analysis of 391 cases and 1286 of their close contacts. medRxiv . 2020.
  52. Mitjà O, Clotet B. Use of antiviral drugs to reduce COVID-19 transmission. Lancet Glob Health . 2020.
  53. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med . 2020;5;382(10):929-936.
  54. Warren TK, Jordan R, Lo MK, et al Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature . 2016;17;531(7594):381-385.
  55. Grein J, Ohmagari N, Shin D. et.al. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med . 2020.
  56. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med . 2020.
  57. Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.Thorax . 2004;59(3):252-256.
  58. To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.Lancet Infect Dis . 2020.
  59. Madelain V, Nguyen T HT, Olivo A, et al. Ebola virus Infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. J Clinical Pharmacokinetics . 2016;55(8):907-923.
  60. Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an Open-label control Study. Engineering . 2020.
  61. Zhang C, Wu Z, Li JW, et al. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents . 2020;105954.